This phase III trial compares six months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab.
Learn more about the A012303 – Shortstop-HER2 trial or by calling the Cancer Research Office at Phoenixville Hospital at 610-983-1811 or Reading Hospital at 484-628-8193.
